Immune Thrombocytopenic Purpura (ITP)
The agent is already approved to treat thrombocytopenia in adults with chronic ITP for whom prior therapy was unsuccessful.
Oral avatrombopag shows promise in kids with ITP, offering a safer, effective alternative to current treatments.
The results are reported from an international cohort and support adding the agent to plasma exchange and immunosuppression.
Dapsone demonstrates efficacy and acceptable safety with low costs as treatment for pediatric ITP.
Gut microbiota modulates bleeding risk in pediatric patients with immune thrombocytopenia.
Mairéad Ní Chonghaile, RGN, BNS, MSc, speaks on the need for training and support networks in this area of care.
Efgartigimod, a first-in-class IgG1 Fc fragment, promisingly separated from placebo in patients with chronic ITP.
The group continues their analysis of emergencies by exploring immune thrombocytopenic purpura.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.